The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Official Title: Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Study ID: NCT03613727
Brief Summary: This phase 2 trial studies the effect of intravenous (IV) vitamin C repletion after myeloablative allogeneic stem cell transplant.
Detailed Description: Vitamin C is a nutritional supplement that can help fight inflammation. Most patients who have a stem cell transplant have lower than normal levels of vitamin C in their blood. Patients will receive intravenous Vitamin C the day after transplant for two weeks, followed by oral vitamin C until six months after transplant. The effect of the Vitamin C on non-relapse mortality (NRM), time to engraftment, rate of acute graft-versus-host disease and to characterize the safety and tolerability of the vitamin C regimen.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Virginia Commonwealth University/ Massey Cancer Center, Richmond, Virginia, United States
Name: William B Clark, MD
Affiliation: Massey Cancer Center
Role: PRINCIPAL_INVESTIGATOR